Clinical trials: Other Cancers
Advanced Malignancies
Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies
Part 2 Cohorts A and C This study is being conducted to test the safety and pharmacokinetics of cemiplimab in patients with lung cancer.
- Trial name
- NCT03233139
- Testing
- Cemiplimab, Ipilimumab, Platinum-doublet chemotherapy
- Where
- 20 sites in Japan
- Volunteers
- 146 people
- Sponsor
- Regeneron Pharmaceuticals
Neurofibromatosis 2, Dermatology/Skin - Other
Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15
.Neurofibromatosis type 2 is an inherently autosomal dominant genetic disease, but cases of mosaicism or de novo mutation are not uncommon. the prevalence is estimated at 1 / 60,000.
- Trial name
- NCT03893643
- Testing
- no intervention
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Prostate Cancer, Metastatic Prostate Adenocarcinoma
Tumor Molecular Profiling in Patients With Prostate Cancer
The aim of the study was to evaluate the prevalence, the prognostic and predictive value of gene alterations in unselected patients with prostate cancer.
- Trial name
- NCT05573789
- Testing
- Tumor molecular profiling
- Where
- Greece
- Volunteers
- 220 people
- Sponsor
- Hellenic Cooperative Oncology Group
Prostate Cancer, Pesticide Exposures
Agriculture Health Study
The "Agricultural Health Study" (AHS) is a collaborative effort between the National Cancer Institute and the National Institute of Environmental Health Sciences. The U.S.
- Conditions
- Prostate Cancer, Pesticide Exposures, Lymphoma, Multiple Myeloma
- Trial name
- NCT00352924
- Where
- United States
- Volunteers
- 89,655 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck, Squamous Cell Cancer
Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer
The purpose of this study is to find out what effects, good and/or bad, 2 doses of Cetuximab will have on head and neck cancer. The study is done because 250 mg/m2 given weekly does not work very well.
- Trial name
- NCT00661427
- Testing
- cetuximab
- Where
- 17 sites in United States
- Volunteers
- 61 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of TY-1091 in Patients With Advanced Solid Tumors
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of TY-1091 administered orally in…
- Conditions
- RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer, Neoplasms
- Trial name
- NCT05675605
- Testing
- TY-1091
- Where
- China
- Volunteers
- 248 people
- Sponsor
- TYK Medicines, Inc
Metastatic Breast Cancer
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
DESTINY-Breast 08 will investigate the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other therapies in patients with Metastatic HER2-low Advanced or Metastatic Breast Cancer
- Trial name
- DB-08 (NCT04556773)
- Testing
- Trastuzumab deruxtecan, Durvalumab, Paclitaxel
- Where
- 37 sites in United States, Australia and 8 more
- Volunteers
- 138 people
- Sponsor
- AstraZeneca
B-cell Non-Hodgkin Lymphoma
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
This is a Phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with Relapsed/Refractory B-cell Non-Hodgkin…
- Trial name
- Lumi-NHL (NCT07123454)
- Testing
- AZD4512
- Where
- 23 sites in United States, Australia and 6 more
- Volunteers
- 91 people
- Sponsor
- AstraZeneca
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by Surgery
RATIONALE: Biliary stenting is the placement of a tube in the bile ducts to keep a blocked area open. Photodynamic therapy uses a drug, such as porfimer sodium, that is absorbed by tumor cells.
- Trial name
- Photostent-02 (NCT00513539)
- Testing
- porfimer sodium, biliary stenting
- Where
- 4 sites in United Kingdom
- Volunteers
- 92 people
- Sponsor
- University College, London
Multiple Myeloma
Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma
Elranatamab is a bispecific antibody: binding of elranatamab to CD3- expressing T-cell and BCMA- expressing multiple myeloma cells causes targeted T-cell mediated cytotoxicity.
- Trial name
- MAGNETISMM17 (NCT05462639)
- Testing
- Elranatamab (PF-06863135)
- Where
- 36 sites in United States, Canada
- Sponsor
- Pfizer
Oncology, MEK Mutation
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway…
- Conditions
- Oncology, MEK Mutation, RAF Gene Mutation, Ras (KRAS or NRAS) Gene Mutation
- Trial name
- NST-628 (NCT06326411)
- Testing
- NST-628
- Where
- 23 sites in United States, Australia
- Volunteers
- 230 people
- Sponsor
- Nested Therapeutics, Inc
Lymphoma
Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant
RATIONALE: Studying samples of blood in the laboratory from patients who have undergone a donor bone marrow transplant may help doctors learn more about changes that occur in DNA and identify biomarkers related to…
- Trial name
- NCT00898612
- Where
- United States
- Sponsor
- Mayo Clinic
Chronic Lymphocytic Leukemia, B-cell Malignancies
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
The primary objective of the study for Cohort 1 and Cohort 2 is to assess the anticancer activity of emavusertib in combination with zanubrutinib in participants with CLL.
- Trial name
- NCT07271667
- Testing
- Emavusertib, Zanubrutinib
- Where
- 11 sites in United States, Italy and 1 more
- Volunteers
- 108 people
- Sponsor
- Curis, Inc.
Acute Myeloid Leukemia, IDH1 Gene Mutation
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia
Among the most notable cancer genome-wide sequencing discoveries in recent years was the finding of mutation hot-spots in the isocitrate dehydrogenase (IDH) genes in grade II/III astrocytomas and oligodendrogliomas and in…
- Conditions
- Acute Myeloid Leukemia, IDH1 Gene Mutation, IDH2 Gene Mutation
- Trial name
- Euro_IDH_AML (NCT04369287)
- Where
- Italy
- Volunteers
- 654 people
- Sponsor
- Istituto Clinico Humanitas
Relapsed or Refractory AML and Other Hematologic Malignancies
Phase I Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Other Hematologic Malignancies.
This is the first in human study of KK2845. This clinical trial consists of Part 1 (Dose Escalation) and Part 2 (Backfill). For patients with relapsed or refractory acute myeloid leukemia (AML) and other Hematologic Malignancies…
- Trial name
- NCT06812104
- Testing
- KK2845_1, KK2845_2, KK2845_3
- Where
- 17 sites in Japan
- Volunteers
- 156 people
- Sponsor
- Kyowa Kirin Co., Ltd.
HNSCC, NSCLC
Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy
Inhibitors of the programmed cell death protein 1 (PD-1)/PD-L1 immune checkpoint signaling pathway are already approved in the treatment of various tumor entities in relapsed or metastatic stages.
- Conditions
- HNSCC, NSCLC, Esophageal Cancer, Urothelial Carcinoma
- Trial name
- ST-ICI02 (NCT04892849)
- Testing
- Conventional Therapy acc. to prevailing clincal approved schemes
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Paraganglioma/ Phaeochromocytoma, Melanoma and Other Malignant Neoplasms of Skin
An International Study on Pediatric Patients With Rare Tumors.
The PARTNER study is an international, prospective, observational study of paediatric patients with very rare tumours.
- Conditions
- Paraganglioma/ Phaeochromocytoma, Melanoma and Other Malignant Neoplasms of Skin, Gastrointestinal Stromal Tumor (GIST), Adrenocortical Tumor
- Trial name
- PARTNER (NCT07072143)
- Where
- Italy
- Volunteers
- 6,250 people
- Sponsor
- Azienda Ospedaliera di Padova
Non-Small Cell Lung Cancer, Small Cell Lung Cancer
SYS6090 Combination Therapy in Advanced Lung Cancer
This is an open-label, multi-cohort, multicenter Phase Ib/II clinical study designed to evaluate the safety, tolerability, and efficacy of SYS6090 injection in combination with chemotherapy or chemotherapy and bevacizumab or…
- Trial name
- NCT07472647
- Testing
- SYS6090 + pemetrexed + platinum-based chemotherapy, SYS6090 + paclitaxel + platinum-based chemotherapy, SYS6090 + docetaxel
- Volunteers
- 596 people
- Sponsor
- Shanghai JMT-Bio Inc.
Brain Cancer, Thyroid Cancer
Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
Background: The field of nuclear medicine has changed a lot in the past decades. Technology has gotten better, so patients are exposed to less radiation. But now workers are doing procedures more often and using lead aprons less.
- Conditions
- Brain Cancer, Thyroid Cancer, Circulatory Disease, Breast Cancer
- Trial name
- NCT02911155
- Where
- United States
- Volunteers
- 229 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor
A Phase 1 Study of BHV-1530 in Advanced Solid Tumors
This is a Phase 1, first in human (FIH), Open-Label, Dose Escalation, Dose Expansion and Dose Optimization Study of BHV-1530 as Monotherapy and in Combination with Other Anti-Cancer Agents in Adult Participants with Advanced or…
- Trial name
- NCT06874335
- Testing
- BHV-1530, Cemiplimab
- Where
- 17 sites in United States
- Volunteers
- 140 people
- Sponsor
- Biohaven Therapeutics Ltd.